Northeast Pharmaceutical Group Co., Ltd.
Symbol: 000597.SZ
SHZ
4.66
CNYTrhová cena dnes
19.6168
Pomer P/E
-0.2211
Pomer PEG
6.66B
MRK Cap
- 0.02%
Výnos DIV
Northeast Pharmaceutical Group Co., Ltd. (000597-SZ) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 20024.02 | 5651.2 | 3844.9 | 2550.4 | |||||||||||||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||
balance-sheet.row.net-receivables | 11582.19 | 2616.6 | 2840.9 | 2956.8 | |||||||||||||||||||||||||||||||
balance-sheet.row.inventory | 5402.13 | 1364.1 | 1220.4 | 1247.3 | |||||||||||||||||||||||||||||||
balance-sheet.row.other-current-assets | 352.48 | 151.2 | 24.3 | 44.9 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-current-assets | 37360.81 | 9783.1 | 7930.5 | 6799.3 | |||||||||||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 18042.19 | 4511.2 | 4852.5 | 5226.4 | |||||||||||||||||||||||||||||||
balance-sheet.row.goodwill | 104.47 | 26.1 | 26.1 | 26.1 | |||||||||||||||||||||||||||||||
balance-sheet.row.intangible-assets | 3305.87 | 824.5 | 828.6 | 952 | |||||||||||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 3410.34 | 850.6 | 854.7 | 978.1 | |||||||||||||||||||||||||||||||
balance-sheet.row.long-term-investments | 1.41 | 0 | 0 | 2.2 | |||||||||||||||||||||||||||||||
balance-sheet.row.tax-assets | 486.64 | 128.1 | 109.2 | 102.1 | |||||||||||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 123.57 | 0.7 | 63.4 | 71.3 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 22064.14 | 5490.6 | 5879.8 | 6380.2 | |||||||||||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-assets | 59424.95 | 15273.7 | 13810.3 | 13179.5 | |||||||||||||||||||||||||||||||
balance-sheet.row.account-payables | 12329.58 | 1398.1 | 4320.5 | 3695.8 | |||||||||||||||||||||||||||||||
balance-sheet.row.short-term-debt | 17072.17 | 6527.4 | 1976.8 | 3179.8 | |||||||||||||||||||||||||||||||
balance-sheet.row.tax-payables | 300.92 | 55.6 | 155.6 | 65.2 | |||||||||||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 1575.12 | 352.8 | 255.9 | 218 | |||||||||||||||||||||||||||||||
Deferred Revenue Non Current | 641.17 | 157.1 | 174.7 | 194 | |||||||||||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 18.94 | - | - | - | |||||||||||||||||||||||||||||||
balance-sheet.row.other-current-liab | 3236.7 | 1511.8 | 1933.1 | 11 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 2571.93 | 389.3 | 673.9 | 690.6 | |||||||||||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 114.15 | 31.3 | 17.9 | 18 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-liab | 39075.25 | 9957.8 | 9097.1 | 8889.2 | |||||||||||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||
balance-sheet.row.common-stock | 5726.84 | 1429.1 | 1434.3 | 1347.9 | |||||||||||||||||||||||||||||||
balance-sheet.row.retained-earnings | 3762.51 | 1013.4 | 805.2 | 496.1 | |||||||||||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 6516.79 | 462.4 | 296.9 | 425.2 | |||||||||||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3512.39 | 2083.4 | 2022.9 | 1874.6 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 19518.53 | 4988.3 | 4559.3 | 4143.7 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 59424.95 | 15273.7 | 13810.3 | 13179.5 | |||||||||||||||||||||||||||||||
balance-sheet.row.minority-interest | 674.05 | 170.5 | 153.9 | 146.5 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-equity | 20192.58 | 5158.7 | 4713.3 | 4290.3 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 59424.95 | - | - | - | |||||||||||||||||||||||||||||||
Total Investments | 1.41 | 0 | 0 | 2.2 | |||||||||||||||||||||||||||||||
balance-sheet.row.total-debt | 18700.31 | 6911.5 | 2232.7 | 3397.8 | |||||||||||||||||||||||||||||||
balance-sheet.row.net-debt | -1323.7 | 1260.3 | -1612.2 | 847.4 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 346.04 | 358.5 | 357 | 95.4 | ||||||||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | -4.3 | 575.1 | 561.1 | 550.9 | ||||||||||||||||||||||||||
cash-flows.row.deferred-income-tax | -354.72 | -18.9 | -7.2 | -13.2 | ||||||||||||||||||||||||||
cash-flows.row.stock-based-compensation | 102.23 | -1899.7 | 79.8 | -1.2 | ||||||||||||||||||||||||||
cash-flows.row.change-in-working-capital | 100.67 | -647 | 254 | -113.6 | ||||||||||||||||||||||||||
cash-flows.row.account-receivables | 149.06 | 149.1 | 115 | -268.9 | ||||||||||||||||||||||||||
cash-flows.row.inventory | -150.94 | -150.9 | -5.6 | 8.3 | ||||||||||||||||||||||||||
cash-flows.row.account-payables | 0 | -747.7 | 151.8 | 160.3 | ||||||||||||||||||||||||||
cash-flows.row.other-working-capital | 102.54 | 102.5 | -7.2 | -13.2 | ||||||||||||||||||||||||||
cash-flows.row.other-non-cash-items | 377.38 | 2218.9 | -136.1 | 228.2 | ||||||||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 567.29 | 0 | 0 | 0 | ||||||||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -249.37 | -235.4 | -244.1 | -119.8 | ||||||||||||||||||||||||||
cash-flows.row.acquisitions-net | 0.42 | 7.5 | 3.2 | 7.8 | ||||||||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | -500 | ||||||||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 15.9 | ||||||||||||||||||||||||||
cash-flows.row.other-investing-activites | 0.42 | 0 | -15.4 | 496 | ||||||||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -248.95 | -228 | -256.3 | -100.1 | ||||||||||||||||||||||||||
cash-flows.row.debt-repayment | -3639 | -1749.6 | -3355.7 | -4061.6 | ||||||||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 7.4 | ||||||||||||||||||||||||||
cash-flows.row.common-stock-repurchased | -14.22 | -14.2 | 0 | -7.4 | ||||||||||||||||||||||||||
cash-flows.row.dividends-paid | -235.2 | -142.9 | -109.5 | -165.5 | ||||||||||||||||||||||||||
cash-flows.row.other-financing-activites | 943.99 | -1183.1 | 3406.1 | 4094.7 | ||||||||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 254.79 | 381.1 | -59 | -132.4 | ||||||||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 10.09 | 6.3 | 6.9 | -1.7 | ||||||||||||||||||||||||||
cash-flows.row.net-change-in-cash | 1727.72 | 1806.3 | 800.2 | 512.4 | ||||||||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 16470 | 5651.2 | 2020.8 | 1220.6 | ||||||||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 14742.27 | 3844.9 | 1220.6 | 708.3 | ||||||||||||||||||||||||||
cash-flows.row.operating-cash-flow | 567.29 | 586.8 | 1108.6 | 746.5 | ||||||||||||||||||||||||||
cash-flows.row.capital-expenditure | -249.37 | -235.4 | -244.1 | -119.8 | ||||||||||||||||||||||||||
cash-flows.row.free-cash-flow | 317.92 | 351.3 | 864.4 | 626.7 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 7791.84 | 8161.4 | 8808.9 | 8145.1 | |||||||||||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 4811.3 | 5021.2 | 5377.4 | 4928.9 | |||||||||||||||||||||||||||||||
income-statement-row.row.gross-profit | 2980.54 | 3140.2 | 3431.5 | 3216.2 | |||||||||||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||
income-statement-row.row.research-development | 98.77 | - | - | - | |||||||||||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 167.44 | - | - | - | |||||||||||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1611.42 | - | - | - | |||||||||||||||||||||||||||||||
income-statement-row.row.other-expenses | -110.08 | -188.1 | 498.2 | 452.3 | |||||||||||||||||||||||||||||||
income-statement-row.row.operating-expenses | 2472.45 | 2773.8 | 2977.5 | 2859.9 | |||||||||||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 7283.75 | 7795.1 | 8354.8 | 7788.8 | |||||||||||||||||||||||||||||||
income-statement-row.row.interest-income | 167.26 | 155.1 | 93.9 | 55.9 | |||||||||||||||||||||||||||||||
income-statement-row.row.interest-expense | 76.68 | 78.4 | 92.1 | 120.2 | |||||||||||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1611.42 | - | - | - | |||||||||||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 35.92 | 121.8 | 158.1 | -228.2 | |||||||||||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -110.08 | -188.1 | 498.2 | 452.3 | |||||||||||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 35.92 | 121.8 | 158.1 | -228.2 | |||||||||||||||||||||||||||||||
income-statement-row.row.interest-expense | 76.68 | 78.4 | 92.1 | 120.2 | |||||||||||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 354.3 | 575.1 | 561.1 | 550.9 | |||||||||||||||||||||||||||||||
income-statement-row.row.ebitda-caps | 808.58 | - | - | - | |||||||||||||||||||||||||||||||
income-statement-row.row.operating-income | 454.28 | 366.4 | 367.4 | 348.3 | |||||||||||||||||||||||||||||||
income-statement-row.row.income-before-tax | 490.21 | 488.2 | 525.4 | 120.2 | |||||||||||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 127.72 | 112.2 | 168.4 | 24.7 | |||||||||||||||||||||||||||||||
income-statement-row.row.net-income | 346.04 | 358.5 | 350.3 | 99 |
Často kladené otázky
Čo je Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) celkové aktíva?
Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) celkové aktíva sú 15273653642.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 3741965029.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.383.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je 0.222.
Aká je čistá zisková marža podniku?
Čistá zisková marža je 0.044.
Aké sú celkové výnosy podniku?
Celkové príjmy sú 0.058.
Aká je Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je 358458434.000.
Aký je celkový dlh firmy?
Celkový dlh je 6911502925.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 2773844602.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 5818314220.000.